Received Sep 24, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
I've also been vaccinated for the shingles after the fact; I still have flare ups; The nerve pain is still lingering; This serious case was reported by a consumer via interactive digital media and described the occurrence of vaccination failure in a adult female patient who received Herpes zoster (Shingrix) for prophylaxis. On an unknown date, the patient received Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced vaccination failure (Verbatim: I've also been vaccinated for the shingles after the fact) (serious criteria GSK medically significant), shingles (Verbatim: I still have flare ups) and nerve pain (Verbatim: The nerve pain is still lingering). The outcome of the vaccination failure was not reported and the outcome of the shingles and nerve pain were not resolved. It was unknown if the reporter considered the vaccination failure, shingles and nerve pain to be related to Shingrix. The company considered the vaccination failure to be unrelated to Shingrix. It was unknown if the company considered the shingles and nerve pain to be related to Shingrix. Additional Information: GSK Receipt Date: 10-SEP-2025 and 11-SEP-2025 This case was reported by a patient via interactive digital media. Consumer reported that it's been over 8 years for and still had flare ups. The reporter mentioned she had also been vaccinated for the shingles after the fact. The nerve pain was still lingering. This case was considered as suspected vaccination failure as details regarding completion of primary vaccination schedule, time to onset and laboratory test confirming shingles were unknown at the time of reporting.; Sender's Comments: A case of Vaccination failure, unknown time after receiving Shingrix, in a adult female patient. Based on the available information a?possible causality that the event was caused by the GSK product cannot be ascertained. Consent for further follow-up has not been received.